Conmed (CNMD) Tops Q4 EPS by 1c

Conmed (NYSE: CNMD) reported Q4 EPS of $1.07, $0.01 better than the analyst estimate of $1.06. Revenue for the quarter came in at $274 million versus the consensus estimate of $278.76 million.

GUIDANCE:

Conmed sees FY2022 EPS of $3.60-$3.85, versus the consensus of $3.74. Conmed sees FY2022 revenue of $1.075-1.125 billion, versus the consensus of $1.11 billion.

For earnings history and earnings-related data on Conmed (CNMD) click here.

You May Also Be Interested In

• 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
• MIND Technology (MIND) Misses Q1 EPS by 5c
• Lands' End (LE) Tops Q1 EPS by 8c ; Offers Guidance